<DOC>
	<DOCNO>NCT00826228</DOCNO>
	<brief_summary>Individuals spinal cord injury sustain significant loss bone mass low extremity ( 20-40 % ) . This study evaluate ability PTH weight-bearing , two intervention build bone , increase bone mass population .</brief_summary>
	<brief_title>Effect Parathyroid Hormone ( PTH ) Weight-Bearing Bone Spinal Cord Injury ( SCI )</brief_title>
	<detailed_description>This pilot project aim evaluate PTH weight-bearing group individual chronic SCI loss bone mass low extremity . A convenience sample 12 people SCI enrol 6 month study assess effect weight-bearing regime plus daily PTH ( Forteo 20ug sc ) BMD bone marker . Subjects evaluate 3 6 month initiate treatment measurement bone density well bone marker formation resorption . An optional extension 12 month offer subject .</detailed_description>
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Spinal Cord Injuries</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>1 . Age 1875 year 2 . Complete SCI total loss motor function level lesion 3 . Capable position DEXA perform 4 . Capable undertake weightbearing exercise regime 5 . Capable read understanding inform consent document 6 . Able selfadminister PTH someone family 7 . T score &lt; 2.5 Z score &lt; 1.5 evaluation total hip BMD 8 . No known endocrinopathies 9 . Normal TSH level 10 . Normal 25OH vitamin D level 11 . Normal calcium level 12 . Normal renal function ( creatinine &lt; 2.0mg/dl ) 13 . Able return followup visit 1 . Surgical intervention result metal anatomy preclude obtain DEXA and/or MRI measurements 2 . Other medical condition opinion investigator would preclude subject complete study 3 . History malignancy 4 . History radiation therapy 5 . Unable selfadminister PTH administer 6 . Elevated liver function test &gt; 2x normal 7 . For male , significantly abnormal free testosterone level 8 . Currently prescribe anticonvulsant 9 . Currently prescribed glucocorticoid , inhale glucocorticoid 10 . Currently prescribe boneactive agent , include bisphosphonate , raloxifene , hormone therapy ( estrogen estrogen/progestin ) , calcitonin strontiumcontaining compound . 11 . No previous history bisphosphonate use 12 . No previous use bonespecific agent past 2 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>